SS
KYTX icon

SBI Securities’s Kyverna Therapeutics KYTX Stock Holding History

SBI Securities’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.78K Buy
+200
New +$1.77K ﹤0.01% 2592
2026
Q1 		– Sell
-22
Closed -$207 – 4174
2025
Q4 		$207 Sell
22
-115
-84% -$854 ﹤0.01% 3203
2025
Q3 		$822 Sell
137
-23
-14% -$92 ﹤0.01% 2775
2025
Q2 		$491 Buy
160
+20
+14% +$49 ﹤0.01% 2973
2025
Q1 		$270 Hold
140
– – ﹤0.01% 3110
2024
Q4 		$524 Buy
+140
New +$671 ﹤0.01% 2875

Other funds holding KYTX

YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
WB
WesBanco Bank Wheeling, West Virginia $4.02B AUM 32.62% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
EI
Ethic Inc New York $8.02B AUM 45.39% 1-Year Est. Return
SIC
Samalin Investment Counsel Chappaqua, New York $320M AUM 20.87% 1-Year Est. Return
CAI
Capital Advisors Inc Tulsa, Oklahoma $6.8B AUM 26.96% 1-Year Est. Return

SBI Securities's KYTX Position: Q2 2026 in Review

SBI Securities opened a new position in Kyverna Therapeutics (KYTX) in Q2 2026: 200 shares worth $1.78K. The stake represents ﹤0.01% of the portfolio and ranks #2592 among its holdings. This is a return to the name: SBI Securities previously reported a position in KYTX as recently as Q4 2025.

SBI Securities first reported a position in KYTX in Q4 2024 and has held it in 6 quarters since. 21 funds tracked by Wall St. Rank hold KYTX as of Q2 2026.

  • SBI Securities held 200 shares of Kyverna Therapeutics worth $1.78K as of Q2 2026.
  • Kyverna Therapeutics was a new SBI Securities position in Q2 2026.
  • Kyverna Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q2 2026, its #2592 holding.
  • SBI Securities first reported a position in Kyverna Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 21 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2026.

Based on SBI Securities's 13F filing for Q2 2026, filed 23 Jul 2026.